IDH2 and acute myeloid leukemia: Interestingly, IDH mutations are common in several types of cancers, including ∼80% of glioblastomas, ∼40% chondrosarcomas, 20% of acute myeloid leukemias (AML), ∼55% sinonasal undifferentiated carcinoma, and 1% prostate cancer (Table 1; Amary et al., 2011; Pansuriya et al., 2011; Liu et al., 2013; Adam et al., 2014; Abeshouse et al., 2015).